CRISPR

Biotech Jason Mast

STAT Plus: Prime and Beam, born of same lab, pursuing rival gene-editing treatments

Biotech Jason Mast

STAT Plus: CRISPR company Arbor Biotechnologies gets cash infusion from ARCH

Biotech Jason Mast

STAT Plus: Beam Therapeutics says CRISPR treatment shows encouraging results in lung condition

Biotech Adam Feuerstein

STAT Plus: Biotech is in a dark place

The Readout LOUD Elaine Chen and Adam Feuerstein

Crisis in CRISPR world, RFK Jr.’s promises, and a novel non-opioid pain drug

Special Report Jason Mast

STAT Plus: The CRISPR companies are not OK

Biotech Andrew Joseph

STAT Plus: Vertex, U.K. reach reimbursement deal for CRISPR-based medicine for sickle cell disease

Biotech Jason Mast

STAT Plus: Editas, after slow start, outlines plan to catch other CRISPR companies

Biotech Jason Mast

STAT Plus: Scribe Therapeutics becomes latest CRISPR company to announce layoffs 

Don't Miss STAT Staff

STAT stories you might have missed in 2024

Biotech Jason Mast

STAT Plus: This father built a gene therapy for his son. Now comes the harder part: saving others’ children, too

Pharma Adam Feuerstein and Jonathan Wosen

STAT Plus: Sanofi advances a drug for a rare, platelet-destroying disease

The Readout Meghana Keshavan

STAT Plus: More beef in the gene editing space

Biotech Jason Mast

STAT Plus: Intellia says CRISPR therapy shows superior gain for cardiomyopathy patients

Biotech Adam Feuerstein and Jason Mast

STAT Plus: Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment

Who to Know Megan Molteni

STAT Plus: These 10 scientists are leading a new generation of gene editors developing CRISPR medicines

Biotech Jason Mast

STAT Plus: Feud between Prime and Tessera, two gene-editing companies, spills out into public

Biotech Jason Mast

STAT Plus: Editas tacks again, steering from lead sickle cell treatment to new one

Biotech Jason Mast

STAT Plus: SalioGen Therapeutics hit by layoffs, as gene-editing biotechs continue to struggle

The Readout LOUD Allison DeAngelis and Adam Feuerstein

Crypto for CRISPR, a new RNAi startup, & a Nobel for AI

Biotech Jason Mast

STAT Plus: As U.S. efforts stall, China pushes ahead with CRISPR treatments for muscular dystrophy

Exclusive Megan Molteni

STAT Plus: A pariah in science, the ‘CRISPR babies’ researcher gains support from a U.S. cryptocurrency entrepreneur

Biotech Jason Mast

STAT Plus: Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb

Biotech Andrew Joseph

STAT Plus: Vertex, U.K. reach deal to provide CRISPR-based medicine to thalassemia patients in England

In the Lab Megan Molteni

STAT Plus: The race to build better CRISPR delivery vehicles is heating up

Exclusive Megan Molteni

STAT Plus: Jiankui He, creator of CRISPR-edited children, relocates to a Chinese medical tourism hub

In the Lab Jason Mast

STAT Plus: Trying to outrun her prion disease, researcher creates powerful epigenetic editor in mice

Biotech Jason Mast

STAT Plus: Intellia’s CRISPR-based treatment dramatically reduced patients’ swelling attacks in small trial

In the Lab Megan Molteni

STAT Plus: ChatGPT for genomes: introducing a CRISPR-designing generative AI